Last reviewed · How we verify
NCT05954364: SAGE-PsA
Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis
trial in Psoriatic Arthritis in 540 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Women's College Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 540 |
| Start date | 23 January 2023 |
| Primary completion | 30 June 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Canada |
Conditions studied
- Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
Sponsor
Women's College Hospital
Who can join
18 and older, any sex, with Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sex and gender are important factors that influence treatment response in PsA. The goal of this multi-centre observational study is to understand how sex and gender influence response to advanced therapies in psoriatic arthritis (PsA). The investigators hope to discover biological and socio-cultural mechanisms that explain the differences in treatment response between men and women with PsA. The study investigators plan to recruit patients from approximately 30 sites across the world. Men and women with active PsA will be assessed before and after they start advanced therapies and information will be collected about sex- and gender-related factors through questionnaires and physical examination. Physicians will assess the patient response to treatment. The investigators will compare the response to treatment in men and women and assess what biological and socio-cultural factors contribute to differences in treatment response.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05954364
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Psoriatic Arthritis
Currently open trials in the same condition.
- NCT07286058 — Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis · Phase 3 · recruiting
- NCT07295509 — A Study of Picankibart in Patients With Active Psoriatic Arthritis · Phase 2, PHASE3 · recruiting
- NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
- NCT07180537 — Creating Health Course Study for People With Rheumatological Conditions · NA · recruiting
- NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
Other Women's College Hospital trials
Trials by the same sponsor.
- NCT07262008 — Sustained Mood Improvement With Laughing Gas Exposure · Phase 3 · not yet recruiting
- NCT07066631 — The Pregnancy and Postpartum Mental Health Optimization Virtual Intervention Network · NA · recruiting
- NCT06852339 — Evaluating the EAPOC-COPD System · NA · not yet recruiting
- NCT07027852 — My Lung Health Coach-A Virtual COPD Self-management Support Program Integrated Into the Electronic Patient Record · NA · recruiting
- NCT06462391 — Adapting and Piloting Acceptance and Commitment Therapy (ACT) for Severe Premenstrual Mood Symptoms · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05954364 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Women's College Hospital
- Last refreshed: 24 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05954364.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing